SKVI
Skinvisible, Inc.0.4300
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.32MP/E (TTM)
-Basic EPS (TTM)
-0.07Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Skinvisible posted steady $5,000 revenue for Q3 ended September 30, 2025, matching last year, with nine-month totals flat at $15,000 y/y. Operating loss narrowed to $106,057 from $124,969 y/y while net loss improved to $250,245 from $286,604, as interest expense dropped; the $38K gap reflects interest expense per statements. Cash dwindled to $645 amid $40K operating outflow, offset by $35K financing inflows, leaving $10M total liabilities against $134K assets. No non-GAAP metrics disclosed in the 10-Q. Patents ticked down to $105K net. Debt overhang looms large.
10-Q
Q2 FY2025 results
Skinvisible held revenues flat at $5,000 in Q2 FY2025 ended June 30, 2025, matching last year, while trimming operating loss to $136K from $143K and net loss to $274K from $303K—interest expense drove the $138K gap. Six-month revenue stayed $10K y/y; net loss narrowed to $555K from $594K. Cash dwindled to $120 amid $41K operating outflow, offset by $35K stock sales, atop $9.9M debt including $5.4M related-party convertibles at 10%. Patents net $110K. Diluted EPS not presented due to anti-dilution from 82M potential shares. Cash stays razor-thin.
10-Q
Q1 FY2025 results
Skinvisible held revenues steady at $5,000 for Q1 ended March 31, 2025, matching last year, while gross profit stayed at $5,000 with zero costs. Operating expenses rose 13.0% yoy to $144,852, driving operating loss to $139,852 from $123,184; net loss narrowed to $281,005 from $290,372, as interest expense fell to $141,153 from $166,408 plus a derivative loss. Cash grew to $13,396 from $10,336 qoq, fueled by $24,780 in stock sales offsetting $31,720 operating outflow—no capex so FCF matches. Convertible notes total $5.7M at 10%, with $352k current. Debt burden weighs heavy.
10-K
FY2024 results
Skinvisible posted FY2024 revenue of $20,000, flat y/y, with gross profit at 100% but operating expenses climbing 19% to $609,589 on higher salaries and audit fees, yielding a net loss of $565,654—sharply improved from 2023's $2.4M hit thanks to a $697k gain on debt settlements while interest ate $669k. No Q4 breakdowns disclosed, but cash edged to $10k amid $88k financing inflows from stock sales; working capital deficit yawned at $3.7M. Quoin's late-2024 trial expansions for QRX003 signal licensing potential. Going concern doubts loom large.
8-K
Quoin's Netherton study advances
Skinvisible's licensee Quoin Pharmaceuticals notched FDA clearance for a Netherton Syndrome whole-body study and showed clinical wins, shifting patients from severe to mild in six weeks—no safety issues. Studies expand to UK, Ireland, Saudi Arabia; licensed in 60 countries. Quoin eyes first FDA nod for Invisicare tech. Success unlocks $5M milestone, royalties for Skinvisible.
IPO
Website
Employees
Sector
Industry
EL
Estee Lauder Companies, Inc. (T
104.39+3.36
ELF
e.l.f. Beauty, Inc.
78.77+0.17
HNST
The Honest Company, Inc.
2.86+0.05
KVUE
Kenvue Inc.
17.25+0.04
NUS
Nu Skin Enterprises, Inc.
10.51+0.01
OVATF
OVATION SCIENCE INC
0.03+0.00
SKIN
The Beauty Health Company
1.41+0.03
SLSN
Solesence, Inc.
2.02+0.00
SNBH
Sentient Brands Holdings Inc.
0.02+0.00
XAGE
Longevity Health Holdings, Inc.
0.44-0.05